Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Börgermann

Showing results (1-10 of 34) with videos related to

Pageof 4
Sort By:
Der Urologe. Ausg. A|November 25, 2011
[Second line therapy for castration-resistant prostate cancer (CRPC)]B Molitor, C Börgermann
Der Internist|October 30, 2007
[Differential therapy of prostate cancer]T Jäger, H Rübben, C Börgermann
Der Urologe. Ausg. A|January 5, 2007
[Palliative therapy concepts for patients with urothelial cancer of the urinary bladder]F Vom Dorp, C Börgermann, H Rübben
Der Urologe. Ausg. A|November 9, 2016
[Treatment costs of localized prostate cancer in Germany : Economic results from the HAROW observational study]T Reinhold, C Dornquast, C Börgermann, et al.
Der Urologe. Ausg. A|January 6, 2007
[The management of cutaneous metastases]C Börgermann, F Vom Dorp, S Krege, et al.
Der Urologe. Ausg. A|August 21, 2009
[Free/total PSA ratio in clinical and ambulatory application. Are different cutoffs justified?]A Swoboda, H-J Luboldt, H Rübben, et al.
Der Urologe. Ausg. A|May 20, 2006
[Therapeutic options for hormone-refractory prostate cancer]K Miller, C Börgermann, J Thüroff, et al.
The Journal of Urology|December 23, 2000
Docetaxel and ifosfamide as second line treatment for patients with advanced or metastatic urothelial cancer after failure of platinum chemotherapy: a phase 2 studyS Krege, V Rembrink, C Börgermann, et al.
Der Urologe. Ausg. A|September 18, 2009
[Characterization of the EGF receptor status in penile cancer : retrospective analysis of the course of the disease in 45 patients]C Börgermann, K J Schmitz, S Sommer, et al.
Der Urologe. Ausg. A|October 21, 2010
[Early detection of prostate cancer: is serum PSA testing alone sufficient?]C Börgermann, F Vom Dorp, G Breuer, et al.
Pageof 4

Showing results (1-10 of 34) with videos related to

Sort By:
Pageof 4
Der Urologe. Ausg. A|November 25, 2011
[Second line therapy for castration-resistant prostate cancer (CRPC)]B Molitor, C Börgermann
Der Internist|October 30, 2007
[Differential therapy of prostate cancer]T Jäger, H Rübben, C Börgermann
Der Urologe. Ausg. A|January 5, 2007
[Palliative therapy concepts for patients with urothelial cancer of the urinary bladder]F Vom Dorp, C Börgermann, H Rübben
Der Urologe. Ausg. A|November 9, 2016
[Treatment costs of localized prostate cancer in Germany : Economic results from the HAROW observational study]T Reinhold, C Dornquast, C Börgermann, et al.
Der Urologe. Ausg. A|January 6, 2007
[The management of cutaneous metastases]C Börgermann, F Vom Dorp, S Krege, et al.
Der Urologe. Ausg. A|August 21, 2009
[Free/total PSA ratio in clinical and ambulatory application. Are different cutoffs justified?]A Swoboda, H-J Luboldt, H Rübben, et al.
Der Urologe. Ausg. A|May 20, 2006
[Therapeutic options for hormone-refractory prostate cancer]K Miller, C Börgermann, J Thüroff, et al.
The Journal of Urology|December 23, 2000
Docetaxel and ifosfamide as second line treatment for patients with advanced or metastatic urothelial cancer after failure of platinum chemotherapy: a phase 2 studyS Krege, V Rembrink, C Börgermann, et al.
Der Urologe. Ausg. A|September 18, 2009
[Characterization of the EGF receptor status in penile cancer : retrospective analysis of the course of the disease in 45 patients]C Börgermann, K J Schmitz, S Sommer, et al.
Der Urologe. Ausg. A|October 21, 2010
[Early detection of prostate cancer: is serum PSA testing alone sufficient?]C Börgermann, F Vom Dorp, G Breuer, et al.
Pageof 4